Welcome to LookChem.com Sign In|Join Free
  • or
Digoxinigenin, a member of the cardiac glycoside family, is a steroid derived from the Digitalis plant. It is characterized by its off-white to pale yellow solid appearance and is known for its therapeutic properties in managing congestive heart failure and other cardiac conditions. Its chemical structure allows it to interact with specific biological targets, making it a versatile molecule with various applications across different industries.

1672-46-4

Post Buying Request

1672-46-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1672-46-4 Usage

Uses

Used in Pharmaceutical Industry:
Digoxinigenin is used as a cardiotonic agent for its positive inotropic activity, which helps in the management of congestive heart failure and other cardiac diseases. It modulates the heart's contractions, improving the overall cardiac function.
Used in Diagnostic Industry:
Digoxinigenin is used as a non-isotopic label for DNA, playing a crucial role in the detection of different viruses. Its ability to bind specifically to target molecules makes it a valuable tool in molecular diagnostics, enhancing the accuracy and efficiency of disease detection.
Used in Research and Development:
In the field of research and development, Digoxigenin serves as a probe for detecting various viruses. Its specificity and versatility make it an essential component in the development of new diagnostic tools and techniques.

Check Digit Verification of cas no

The CAS Registry Mumber 1672-46-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,6,7 and 2 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1672-46:
(6*1)+(5*6)+(4*7)+(3*2)+(2*4)+(1*6)=84
84 % 10 = 4
So 1672-46-4 is a valid CAS Registry Number.
InChI:InChI=1/C23H34O5/c1-21-7-5-15(24)10-14(21)3-4-17-18(21)11-19(25)22(2)16(6-8-23(17,22)27)13-9-20(26)28-12-13/h9,14-19,24-25,27H,3-8,10-12H2,1-2H3

1672-46-4 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Sigma-Aldrich

  • (Y0000640)  Digoxigenin  European Pharmacopoeia (EP) Reference Standard

  • 1672-46-4

  • Y0000640

  • 1,880.19CNY

  • Detail
  • Sigma-Aldrich

  • (D9026)  Digoxigenin  analytical standard

  • 1672-46-4

  • D9026-25MG

  • 418.86CNY

  • Detail
  • Sigma-Aldrich

  • (D9026)  Digoxigenin  analytical standard

  • 1672-46-4

  • D9026-100MG

  • 1,261.26CNY

  • Detail
  • Sigma-Aldrich

  • (D9026)  Digoxigenin  analytical standard

  • 1672-46-4

  • D9026-500MG

  • 4,976.01CNY

  • Detail

1672-46-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name digoxigenin

1.2 Other means of identification

Product number -
Other names Card-20(22)-enolide, 3,12,14-trihydroxy-, (3β,5β,12β)-

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1672-46-4 SDS

1672-46-4Related news

DIGOXIGENIN (cas 1672-46-4) modification of adenovirus to spatially control gene delivery from chitosan surfaces09/28/2019

To spatially control the delivery of multiple viral vectors from biomaterial scaffolds, digoxigenin (DIG) was conjugated to adenoviral capsid proteins as an antigenic determinant for antibody immobilization. The infectivity, toxicity, specificity and immobilization stability of DIG-modified aden...detailed

Notes & TipsElimination of nonspecific bands in non-radioactive electrophoretic mobility shift assays using the DIGOXIGENIN (cas 1672-46-4) system09/27/2019

In the course of detecting nuclear transcription factors by electrophoretic mobility shift assay using digoxigenin (DIG)-labeled probes, we encountered a problem with a considerable nonspecific shift band in negative control lanes from which protein extracts were omitted. This nonspecific shift ...detailed

Competitive homogeneous DIGOXIGENIN (cas 1672-46-4) immunoassay based on fluorescence quenching by gold nanoparticles09/26/2019

We report on a competitive, homogeneous immunoassay for the detection of the hapten digoxigenin. The assay is based on competitive fluorescence quenching by gold nanoparticles. Digoxigenin is indirectly labeled with the fluorophore Cy3B through bovine serum albumin and used as a marker. Gold nan...detailed

The cardenolides strophanthidin, DIGOXIGENIN (cas 1672-46-4) and dihydroouabain act as activators of the human RORγ/RORγT receptors09/25/2019

Two isoforms of a ligand-activated nuclear receptor, RORγ and RORγT, have been implicated in various physiological functions, including energy metabolism, circadian rhythm and immune system development. Using a stably transfected reporter cell line, we screened two chemical libraries and ident...detailed

Synthesis of MeON-neoglycosides of DIGOXIGENIN (cas 1672-46-4) with 6-deoxy- and 2,6-dideoxy-d-glucose derivatives and their anticancer activity09/24/2019

Cardiac glycosides show anticancer activities and their deoxy-sugar chains are vital for their anticancer effects. In order to study the structure-activity relationship (SAR) of cardiac glycosides toward cancers and get more potent anticancer agents, a series of MeON-neoglycosides of digoxigenin...detailed

Research paperSynthesis of C3-Neoglycosides of DIGOXIGENIN (cas 1672-46-4) and their anticancer activities09/10/2019

Cardiac glycosides exhibit significant anticancer effects and the glycosyl substitution at C3 position of digoxigenin is pivotal for their biological activity. In order to study the structure-activity relationship (SAR) of cardiac glycosides toward cancers and explore more potent anticancer agen...detailed

1672-46-4Relevant academic research and scientific papers

Metabolism of digoxin and digoxigenin digitoxosides in rat liver microsomes: Involvement of cytochrome P4503A

Salphati, Laurent,Benet, Leslie Z.

, p. 171 - 185 (1999)

1. The sequential metabolism of digoxin (Dg3) to digoxigenin bis-digitoxoside (Dg2), digoxigenin mono-digitoxoside (Dg1) and digoxigenin (Dg0) was investigated in rat liver microsomes. 2. Kinetic studies produced results consistent with a single enzyme mechanism describing the successive oxidative cleavages. Formation of Dg2 was catalysed with mean (± SD) K(m) and V(max) of 125 ± 22 μM and 362 ± 37 pmol/min/mg protein, respectively. The corresponding values for the formation of Dg1 were 61 ± 5 μM and 7 ± 1 pmol/min/mg protein. Dg0 formation was catalysed with the apparent values of 30 ± 9 μM and 310 ± 30 pmol/min/mg protein. 3. Chemical inhibition of cytochrome P450 (CYP) 3A subfamily with ketoconazole and triacetyoleandomycin decreased the formation of Dg2 and Dg1 by up to 90%. Antibodies specific to rat CYP3A2 lowered the rate of oxidative cleavage of Dg3 and Dg2 by up to 85%. Inhibition of CYP2E1, CYP2C subfamily and CYP1A2 by chemical and immunoinhibition did not affect initial rates of metabolism of Dg3 and Dg2. In contrast, Dg1 metabolism was not affected by triacetyloleandomycin as well as by antibodies to CYP3A2, CYP2C11, CYP2E1, CYP2B1/2B2 and CYP1A2. It was however inhibited by > 80% by gestodene and 17α-ethynylestradiol (selective inhibitors of human CYP3A). 4. Collectively, these data support the involvement of CYP3A in the cleavage of Dg3 and Dg2 in rat liver microsomes. The enzyme-metabolizing Dg1 remains to be identified.

Biotransformation of extracted digitoxin from Digitalis lanata by Streptomyces

Keshk, Sherif,Mostafa,Tawfik,Elshemy

, p. 458 - 462 (2011)

The biotransformation of digitoxin and some of its derivatives extracted from Digitalis lanata by Streptomyces isolated species was investigated. Cultures of a Streptomyces strain designated EUSA-2003B, isolated from an Egyptian soil sample, efficiently induced selective 12β-hydroxylation of the steroid aglycone of digitoxin (DT) and its α-acetyl and β-methyl derivatives. The transformation reaction was performed within a 5-day fermentation process, products were isolated and their aglycone moiety was obtained by acid hydrolysis and their structures were elucidated by 13C and 1H NMR. The biotransformation resulted mainly digoxin (DG,~87%), meanwhile, digoxigenone (DGON,~7.0%)was also afforded as a side product. The present study revealed that: 1-Streptomyces isolate EUSA2003B harbors its specific 12β-hydroxlase and has the capability to transform DT and it's α-acetyl and α-methyl derivatives into their corresponding digoxins at reasonable yields. 2-The minor structural differences in the trisaccharide side chain seemed ineffective on the transformational capability of this organism. 3-The Streptomyces might also possess a specific glycosidase that splits the saccharidic side chain beside another dehydrogenase that oxidizes C3 at the steroid nucleus into its ketone form (DGON).

Na+/K+-ATPase-Targeted Cytotoxicity of (+)-Digoxin and Several Semisynthetic Derivatives

Burdette, Joanna E.,Chen, Xiaozhuo,Cheng, Xiaolin,Heath, Kimberly,Johnson, Michael E.,Kinghorn, A. Douglas,Ren, Jinhong,Ren, Yulin,Ribas, Hennrique T.,Shriwas, Pratik,Wu, Sijin

, (2020/03/05)

(+)-Digoxin (1) is a well-known cardiac glycoside long used to treat congestive heart failure and found more recently to show anticancer activity. Several known cardenolides (2-5) and two new analogues, (+)-8(9)-β-anhydrodigoxigenin (6) and (+)-17-epi-20,22-dihydro-21α-hydroxydigoxin (7), were synthesized from 1 and evaluated for their cytotoxicity toward a small panel of human cancer cell lines. A preliminary structure-activity relationship investigation conducted indicated that the C-12 and C-14 hydroxy groups and the C-17 unsaturated lactone unit are important for 1 to mediate its cytotoxicity toward human cancer cells, but the C-3 glycosyl residue seems to be less critical for such an effect. Molecular docking profiles showed that the cytotoxic 1 and the noncytotoxic derivative 7 bind differentially to Na+/K+-ATPase. The HO-12β, HO-14β, and HO-3′aα hydroxy groups of (+)-digoxin (1) may form hydrogen bonds with the side-chains of Asp121 and Asn122, Thr797, and Arg880 of Na+/K+-ATPase, respectively, but the altered lactone unit of 7 results in a rotation of its steroid core, which depotentiates the binding between this compound and Na+/K+-ATPase. Thus, 1 was found to inhibit Na+/K+-ATPase, but 7 did not. In addition, the cytotoxic 1 did not affect glucose uptake in human cancer cells, indicating that this cardiac glycoside mediates its cytotoxicity by targeting Na+/K+-ATPase but not by interacting with glucose transporters.

17BETA-HETEROCYCLYL-DIGITALIS LIKE COMPOUNDS FOR THE TREATMENT OF HEART FAILURE

-

Page/Page column 0149; 0150; 0151, (2020/02/13)

Disclosed are compounds of formula (I) wherein X, Y, Z are annular atoms comprised in a five-membered carbocyclic or heterocyclic ring, selected from the group consisting of CH, NH, N, O, S; said carbocyclic or heterocyclic ring being optionally substituted with amino (C1-C4) linear or branched alkyl or guanidine or guanidino (C1-C4) linear or branched alkyl; with the proviso that the heterocycle ring is not furyl; n is 0 or 1; R is H or OH; the dotted line represents an optional double bond C=C; the thick line represents a bond in the β configuration; the wavy line represents a bond both in the α and β configuration; their enantiomeric and/or diastereomeric mixtures, their pharmaceutically acceptable salts, their solvates, hydrates; their metabolite and metabolic precursors. The compounds of formula (I) are for use as medicaments, in particular for the treatment of acute or chronic heart failure. Oral administration is also possible.

Effect of cyclodextrins on the acid hydrolysis of digoxin.

Uekama,Fujinaga,Hirayama,Otagiri,Kurono,Ikeda

, p. 627 - 630 (2007/10/02)

The effects of three cyclodextrins (alpha-, beta-, gamma-CyD) on the acid hydrolysis of digoxin were examined. From the high performance liquid chromatographic tracing of each of the four components (digoxin, bisdigitoxoside, monodigitoxoside, digoxigenin) in reaction mixtures, the individual rate constants (K1-K6) were determined by analogue computer simulation. The hydrolysis was suppressed by CyDs in the order of beta-great than gamma-greater than alpha-greater than-CyD, where beta-CyD inhibited the appearance rates of digoxigenin (k3, K5, and K6) significantly. In the dissolution study of digoxin tablets, the increase in dissolution rate and decrease in acid hydrolysis were attained by inclusion complexation. The data are presented suggesting that CyDs are useful for improving the oral bioavailability of digoxin.

14β-HYDROXY STEROIDS-III. SYNTHESIS OF DIGOXIGENIN FROM DEOXYCHOLIC ACID

Welzel, Peter,Stein, Hermann

, p. 3385 - 3388 (2007/10/02)

A new synthetic approach to cardenolides is discussed which employs singlet oxygen addition to dienol ethers and an intramolecular Prins reaction.

14 β-Hydroxy 3-deoxycardenolides

-

, (2008/06/13)

Novel compounds of the formula STR1 useful as pharmaceutical compounds are disclosed. Processes are also disclosed for their preparation.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1672-46-4